<DOC>
	<DOCNO>NCT01256151</DOCNO>
	<brief_summary>To assess sublingual tablet similar pharmacokinetics conventional tablet alprazolam .</brief_summary>
	<brief_title>Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 . Signed informed consent . Evidence history clinically significant abnormality Positive drug screen , excessive alcohol tobacco use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>sublingual</keyword>
	<keyword>alprazolam</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>